This study aims to investigate the possibility of CD44-targeted NIR-PIT in a poorly immunogenic tumor model, MOC2-luc, to induce additional antitumor immunity and sensitize it to anti-PD-1 ICI when given as a combination therapy. Here, CD44 is linked to neoplasm.